Establishing SCID mouse models of B-cell non-Hodgkin's lymphoma

Chinese Journal of Cancer

Volumn 28, Issue 2, 2009, Pages 181-183

  Yan, Jin Song ^a   Chen, Xue Yu ^a   Li, Wei Ping ^a   Yang, Yan ^a   Song, Zhen Lan ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Daudi cell; Lymphoma; Mouse model; Rituximab; SU DHL 4 cell

Indexed keywords

RITUXIMAB;

ABDOMINAL TUMOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CACHEXIA; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; DAUDI CELL; DRUG EFFICACY; FEMALE; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PARALYSIS; REFLEX; SCID MOUSE; SEVERE COMBINED IMMUNODEFICIENCY; SURVIVAL TIME; TUMOR VOLUME; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MICE; MICE, SCID; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70349512725     PISSN: 1000467X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy [J]. J Clin Oncol, 1999,17(1):68-276.
2. Stein R, Qu Z, Chen S, et al. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab [J]. Blood, 2006,108(8):2736-2744.
3. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma [J]. N Engl J Med, 1993,328(14):1002-1006.
4. Montserrat E, Garcia-Conde J, Vinolas N, et al. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphomas: long-term results of a multicenter randomized trial. (PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology) [J]. Eur J Haematol, 1996,57(5):377-383.
5. Smith MR, Jin F, Joshi I. Enhanced efficacy of therapy with antisense BCL-2 oligonucleotides plus anti-CD20 monoclonal antibody in scid mouse/human lymphoma xenografts [J]. Mol Cancer Ther, 2004,3(12):1693-1699.
6. Ghetie MA, Tucker K, Richardson J, et al. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin [J]. Blood, 1992,80(9):2315-2320.
7. Gillies SD, Lan Y, Williams S, et al. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma [J]. Blood, 2005,105(10):3972-3978.
8. Ghetie MA, Richardson J, Tucker T, et al. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice [J]. Int J Cancer, 1990,45(3):481-485.
9. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia [J]. Drugs, 2003,63(8):803-843.
10. Marks PA. Discovery and development of SAHA as an anticancer agent [J]. Oncogene, 2007,26(9):1351-1356.
11. Ludwig H, Khayat D, Giaccone G, et al. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies [J]. Cancer, 2005,104(9):1794-1807.